Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Agios, Aurigene team up for cancer target deal
June 2017
SHARING OPTIONS:

CAMBRIDGE, Mass.—Agios Pharmaceuticals Inc. and discovery-stage biotechnology company Aurigene Discovery Technologies Ltd. have inked a global license agreement, under which they will research, develop and commercialize small-molecule inhibitors of an undisclosed cancer metabolism target. Per the agreement, Agios will receive exclusive rights to Aurigene's portfolio of novel small molecules for the chosen target. Agios will be responsible for conducting preclinical studies, and if those are successful, will fund additional global research and development and regulatory/commercial activities. The agreement includes a $3-million upfront payment, as well as potential future milestone payments of up to $17 million per licensed product if Agios reaches certain development and regulatory milestones. Aurigene will be eligible for low single-digit royalties on sales of any products resulting from this deal.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.